Which has higher earnings & valuation, MRVI or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Maravai LifeSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maravai LifeSciences $185.74M 8.55 -$130.77M -$0.71 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media refer more to MRVI or RGC?

In the previous week, Regencell Bioscience had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 5 mentions for Regencell Bioscience and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.62 beat Regencell Bioscience's score of 0.10 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MRVI or TWST?

In the previous week, Twist Bioscience had 7 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Twist Bioscience and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.62 beat Twist Bioscience's score of 0.22 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CRSP or MRVI?

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 7 mentions for CRISPR Therapeutics and 3 mentions for Maravai LifeSciences. CRISPR Therapeutics' average media sentiment score of 0.68 beat Maravai LifeSciences' score of 0.62 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRVI or XENE?

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 3 mentions for Maravai LifeSciences. Xenon Pharmaceuticals' average media sentiment score of 0.93 beat Maravai LifeSciences' score of 0.62 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or MRVI?

In the previous week, Amneal Pharmaceuticals and Amneal Pharmaceuticals both had 3 articles in the media. Maravai LifeSciences' average media sentiment score of 0.62 beat Amneal Pharmaceuticals' score of 0.49 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maravai LifeSciences (MRVI) Competitors

$6.15 -0.09 (-1.44%)

Closing price 04:00 PM Eastern

Extended Trading

$6.18 +0.03 (+0.55%)

As of 05:08 PM Eastern

Compare

MRVI vs. RGC, TWST, CRSP, XENE, and AMRX

Should you buy Maravai LifeSciences stock or one of its competitors? MarketBeat compares Maravai LifeSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maravai LifeSciences include Regencell Bioscience (RGC), Twist Bioscience (TWST), CRISPR Therapeutics (CRSP), Xenon Pharmaceuticals (XENE), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

How does Maravai LifeSciences compare to Regencell Bioscience?

Maravai LifeSciences (NASDAQ:MRVI) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Maravai LifeSciences has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Regencell Bioscience's return on equity of 0.00% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Regencell Bioscience	N/A	N/A	N/A

In the previous week, Regencell Bioscience had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 5 mentions for Regencell Bioscience and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.62 beat Regencell Bioscience's score of 0.10 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Regencell Bioscience has lower revenue, but higher earnings than Maravai LifeSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	8.55	-$130.77M	-$0.71	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Maravai LifeSciences currently has a consensus target price of $5.50, suggesting a potential downside of 10.57%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Maravai LifeSciences is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Maravai LifeSciences beats Regencell Bioscience on 7 of the 13 factors compared between the two stocks.

How does Maravai LifeSciences compare to Twist Bioscience?

Maravai LifeSciences (NASDAQ:MRVI) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Twist Bioscience has higher revenue and earnings than Maravai LifeSciences. Twist Bioscience is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	8.55	-$130.77M	-$0.71	N/A
Twist Bioscience	$376.57M	16.91	-$77.67M	-$1.33	N/A

Maravai LifeSciences presently has a consensus target price of $5.50, suggesting a potential downside of 10.57%. Twist Bioscience has a consensus target price of $79.30, suggesting a potential downside of 22.44%. Given Maravai LifeSciences' higher probable upside, equities research analysts clearly believe Maravai LifeSciences is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Maravai LifeSciences has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

50.3% of Maravai LifeSciences shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by insiders. Comparatively, 3.1% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Twist Bioscience has a net margin of -19.85% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Twist Bioscience	-19.85%	-26.73%	-19.15%

In the previous week, Twist Bioscience had 7 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Twist Bioscience and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.62 beat Twist Bioscience's score of 0.22 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Twist Bioscience beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Maravai LifeSciences has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,528.36	-$581.60M	-$6.22	N/A
Maravai LifeSciences	$185.74M	8.55	-$130.77M	-$0.71	N/A

CRISPR Therapeutics currently has a consensus price target of $67.78, indicating a potential upside of 21.86%. Maravai LifeSciences has a consensus price target of $5.50, indicating a potential downside of 10.57%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe CRISPR Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 7 mentions for CRISPR Therapeutics and 3 mentions for Maravai LifeSciences. CRISPR Therapeutics' average media sentiment score of 0.68 beat Maravai LifeSciences' score of 0.62 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maravai LifeSciences has a net margin of -51.07% compared to CRISPR Therapeutics' net margin of -13,856.54%. Maravai LifeSciences' return on equity of -17.87% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Summary

CRISPR Therapeutics beats Maravai LifeSciences on 10 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to Xenon Pharmaceuticals?

Maravai LifeSciences (NASDAQ:MRVI) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Maravai LifeSciences has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	8.55	-$130.77M	-$0.71	N/A
Xenon Pharmaceuticals	$7.50M	777.23	-$345.91M	-$4.70	N/A

Maravai LifeSciences has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Maravai LifeSciences presently has a consensus price target of $5.50, indicating a potential downside of 10.57%. Xenon Pharmaceuticals has a consensus price target of $77.20, indicating a potential upside of 28.03%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 3 mentions for Maravai LifeSciences. Xenon Pharmaceuticals' average media sentiment score of 0.93 beat Maravai LifeSciences' score of 0.62 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenon Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Summary

Xenon Pharmaceuticals beats Maravai LifeSciences on 10 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Amneal Pharmaceuticals has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.79	$72.06M	$0.38	44.66
Maravai LifeSciences	$185.74M	8.55	-$130.77M	-$0.71	N/A

In the previous week, Amneal Pharmaceuticals and Amneal Pharmaceuticals both had 3 articles in the media. Maravai LifeSciences' average media sentiment score of 0.62 beat Amneal Pharmaceuticals' score of 0.49 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals presently has a consensus target price of $15.80, indicating a potential downside of 6.89%. Maravai LifeSciences has a consensus target price of $5.50, indicating a potential downside of 10.57%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Amneal Pharmaceuticals is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Amneal Pharmaceuticals beats Maravai LifeSciences on 11 of the 15 factors compared between the two stocks.

Get Maravai LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRVI vs. The Competition

Export

Metric	Maravai LifeSciences	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.59B	$8.28B	$6.79B	$12.54B
Dividend Yield	N/A	2.52%	2.66%	6.15%
P/E Ratio	-8.66	15.70	27.46	25.27
Price / Sales	8.55	7.26	582.89	119.24
Price / Cash	15.27	17.76	48.53	58.59
Price / Book	4.21	3.55	10.95	6.61
Net Income	-$130.77M	$226.25M	$3.57B	$336.83M
7 Day Performance	6.75%	1.68%	2.58%	2.54%
1 Month Performance	29.47%	-2.87%	1.67%	0.46%
1 Year Performance	145.02%	3.97%	35.92%	29.41%

Maravai LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRVI Maravai LifeSciences	1.6601 of 5 stars	$6.15 -1.4%	$5.50 -10.6%	+158.9%	$1.59B	$185.74M	N/A	610
RGC Regencell Bioscience	0.2983 of 5 stars	$11.03 +4.9%	N/A	-64.3%	$5.48B	N/A	N/A	10
TWST Twist Bioscience	1.3899 of 5 stars	$86.06 +1.0%	$71.60 -16.8%	+179.6%	$5.38B	$376.57M	N/A	990	Positive News Analyst Forecast Gap Down
CRSP CRISPR Therapeutics	2.4654 of 5 stars	$55.29 +1.7%	$67.78 +22.6%	+12.2%	$5.37B	$1M	N/A	460
XENE Xenon Pharmaceuticals	3.7293 of 5 stars	$54.49 -0.5%	$77.20 +41.7%	+92.8%	$5.28B	N/A	N/A	210	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRVI) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Competitors

MRVI vs. RGC, TWST, CRSP, XENE, and AMRX

How does Maravai LifeSciences compare to Regencell Bioscience?

Summary

How does Maravai LifeSciences compare to Twist Bioscience?

Summary

How does Maravai LifeSciences compare to CRISPR Therapeutics?

Summary

How does Maravai LifeSciences compare to Xenon Pharmaceuticals?

Summary

How does Maravai LifeSciences compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maravai LifeSciences (MRVI) Competitors

MRVI vs. RGC, TWST, CRSP, XENE, and AMRX

How does Maravai LifeSciences compare to Regencell Bioscience?

Do insiders and institutionals hold more shares of MRVI or RGC?

Which has more risk and volatility, MRVI or RGC?

Is MRVI or RGC more profitable?

Does the media refer more to MRVI or RGC?

Which has higher earnings & valuation, MRVI or RGC?

Do analysts recommend MRVI or RGC?

Summary

How does Maravai LifeSciences compare to Twist Bioscience?

Which has higher valuation & earnings, MRVI or TWST?

Do analysts prefer MRVI or TWST?

Which has more volatility & risk, MRVI or TWST?

Do insiders and institutionals have more ownership in MRVI or TWST?

Is MRVI or TWST more profitable?

Does the media favor MRVI or TWST?

Summary

How does Maravai LifeSciences compare to CRISPR Therapeutics?

Which has preferable valuation & earnings, CRSP or MRVI?

Do analysts prefer CRSP or MRVI?

Do insiders and institutionals hold more shares of CRSP or MRVI?

Which has more volatility & risk, CRSP or MRVI?

Does the media favor CRSP or MRVI?

Is CRSP or MRVI more profitable?

Summary

How does Maravai LifeSciences compare to Xenon Pharmaceuticals?

Which has better earnings & valuation, MRVI or XENE?

Which has more risk & volatility, MRVI or XENE?

Do insiders & institutionals believe in MRVI or XENE?

Do analysts recommend MRVI or XENE?

Does the media refer more to MRVI or XENE?

Is MRVI or XENE more profitable?

Summary

How does Maravai LifeSciences compare to Amneal Pharmaceuticals?

Which has more risk and volatility, AMRX or MRVI?

Is AMRX or MRVI more profitable?

Do institutionals and insiders believe in AMRX or MRVI?

Which has better earnings and valuation, AMRX or MRVI?

Does the media favor AMRX or MRVI?

Do analysts rate AMRX or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools